Search Results - "Busaidy, N. L."

Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study by Pacini, F., Ladenson, P. W., Schlumberger, M., Driedger, A., Luster, M., Kloos, R. T., Sherman, S., Haugen, B., Corone, C., Molinaro, E., Elisei, R., Ceccarelli, C., Pinchera, A., Wahl, R. L., Leboulleux, S., Ricard, M., Yoo, J., Busaidy, N. L., Delpassand, E., Hanscheid, H., Felbinger, R., Lassmann, M., Reiners, C.

“…Context: After surgery for differentiated thyroid carcinoma, many patients are treated with radioiodine to ablate remnant thyroid tissue. This procedure has…”
Get full text

Assessment of the Incremental Value of Recombinant Thyrotropin Stimulation before 2-[18F]-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Imaging to Localize Residual Differentiated Thyroid Cancer by Leboulleux, S., Schroeder, P. R., Busaidy, N. L., Auperin, A., Corone, C., Jacene, H. A., Ewertz, M. E., Bournaud, C., Wahl, R. L., Sherman, S. I., Ladenson, P. W., Schlumberger, M.

“…Purpose: The purpose of the study was to assess prospectively the impact of recombinant human TSH (rhTSH) administration on positron emission tomography…”
Get full text

Follow-Up of Low-Risk Differentiated Thyroid Cancer Patients Who Underwent Radioiodine Ablation of Postsurgical Thyroid Remnants after Either Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal by Elisei, R., Schlumberger, M., Driedger, A., Reiners, C., Kloos, R. T., Sherman, S. I., Haugen, B., Corone, C., Molinaro, E., Grasso, L., Leboulleux, S., Rachinsky, I., Luster, M., Lassmann, M., Busaidy, N. L., Wahl, R. L., Pacini, F., Cho, S. Y., Magner, J., Pinchera, A., Ladenson, P. W.

“…Background: We previously demonstrated comparable thyroid remnant ablation rates in postoperative low-risk thyroid cancer patients prepared for administration…”
Get full text

Selective RET kinase inhibition for patients with RET-altered cancers by Subbiah, V., Velcheti, V., Tuch, B.B., Ebata, K., Busaidy, N.L., Cabanillas, M.E., Wirth, L.J., Stock, S., Smith, S., Lauriault, V., Corsi-Travali, S., Henry, D., Burkard, M., Hamor, R., Bouhana, K., Winski, S., Wallace, R.D., Hartley, D., Rhodes, S., Reddy, M., Brandhuber, B.J., Andrews, S., Rothenberg, S.M., Drilon, A.

“…Alterations involving the RET kinase are implicated in the pathogenesis of lung, thyroid and other cancers. However, the clinical activity of multikinase…”
Get full text

7742 Clinical Outcomes of Thyroid Cancer Patients Enrolled in a Comprehensive Thyroid Cancer Survivorship Program by Ruiz Santillan, M A, Rollins, J L, Lee-Kim, S H, Hu, M I, Sherman, S I, Varghese, J, Busaidy, N L, Cabanillas, M, Dadu, R, Iyer, P C, Ying, A K, Waguespack, S G, Devin, J K, Jimenez, C, Vassilopoulou-Sellin, R, Gagel, R F, Zafereo, M, Graham, P H, Perrier, N D, Grubbs, E, Fisher, S B, Habra, M A

“…Abstract Disclosure: M.A. Ruiz Santillan: None. J.L. Rollins: None. S. Lee-Kim: None. M.I. Hu: None. S.I. Sherman: None. J. Varghese: None. N.L. Busaidy: None…”
Get full text

Treatment (tx) with tyrosine kinase inhibitors (TKIs) for patients (pts) with differentiated thyroid cancer (DTC): The M. D. Anderson Cancer Center (MDACC) experience by Cabanillas, M. E., Waguespack, S. G., Bronstein, Y., Williams, M., Feng, L., Sherman, S. I., Busaidy, N. L.

“…Abstract only 6060 Background: DTC is a relatively common tumor and about 20% will develop distant metastases (mets) of which at least 50% will not respond to…”
Get full text

Phase I study combining an IGFR inhibitor (IMC-A12) and an mTOR inhibitor (temsirolimus) in patients with solid tumors or lymphoma by Naing, A., LoRusso, P., Mills, G., Berry, D., Doyle, L., Rohren, E., Burger, A., Chen, H., Busaidy, N. L., Kurzrock, R.

“…Abstract only e14535 Background: IMC-A12 is a fully humanized IgG1/ lambda monoclonal antibody directed at the type I Insulin-Like Growth Factor Receptor…”
Get full text

Hypocalcemia induced by bisphophonates in cancer patients with vitamin D deficiency by Yazbeck, C. F., Gonzalez-Angulo, A. M., Shaw, S. A., Waguespack, S. G., Vassilopoulou-Sellin, R., Busaidy, N. L.

“…Abstract only 19644 Background: The use of bisphosphonates for treatment of hypercalcemia, bone pain and reduction of skeletal morbidity in metastatic breast…”
Get full text

Survival of resectable pancreatic cancer patients with diabetes by Busaidy, N. L., Yazbeck, C. F., Shah, P., Evans, D. B., Li, D., Geraci, J. M., Weiser, M. A.

“…Abstract only 4098 Background: Pancreatic cancer is the fourth leading cause of cancer mortality in the United States. Determining modifiable prognostic…”
Get full text

Parathyroid carcinoma: A 22-year experience by Busaidy, Naifa L., Jimenez, Camilo, Habra, Mouhammed Amir, Schultz, Pamela N., El-Naggar, Adel K., Clayman, Gary L., Asper, Joshua A., Diaz Jr, Eduardo M., Evans, Douglas B., Gagel, Robert F., Garden, Adam, Hoff, Ana O., Lee, Jeffrey E., Morrison, William H., Rosenthal, David I., Sherman, Steven I., Sturgis, Erich M., Waguespack, Steven G., Weber, Randal S., Wirfel, Kelly, Vassilopoulou-Sellin, Rena

“…Purpose. Because parathyroid carcinoma is rare, clear consensus is not available regarding the optimal management of patients with this condition. Treatment…”
Get full text

Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma by SHEPLER, Todd R, SHERMAN, Steve I, FAUSTINA, Misha-Michelle, BUSAIDY, Naifa L, AMIR AHMADI, M, ESMAELI, Bita

“…A 50-year-old woman presented with a 5-year history of unilateral epiphora that began shortly after 131I therapy for thyroid carcinoma. A recent recombinant…”
Get full text